A Web-Based Therapeutic Program (We Can Do This) for Reducing Methamphetamine Use and Increasing Help-Seeking Among Aboriginal and Torres Strait Islander People: Protocol for a Randomized Wait-List Controlled Trial.

Aboriginal health services Australian Aboriginal people eHealth methamphetamine

Journal

JMIR research protocols
ISSN: 1929-0748
Titre abrégé: JMIR Res Protoc
Pays: Canada
ID NLM: 101599504

Informations de publication

Date de publication:
26 Jul 2019
Historique:
received: 24 03 2019
accepted: 12 06 2019
revised: 12 06 2019
entrez: 1 5 2021
pubmed: 26 7 2019
medline: 26 7 2019
Statut: epublish

Résumé

Methamphetamine use is of deep concern to Aboriginal and Torres Strait Islander communities, but access to culturally appropriate treatment resources and services is limited. Web-based programs have potential as flexible and cost-effective additions to the range of treatment options available to Aboriginal people. The We Can Do This online intervention is designed to incorporate evidence-based therapies in a culturally relevant format using narratives from Aboriginal people to contextualize the therapeutic content. The goal of the research will be to test the effectiveness of the online intervention in a wait-list controlled randomized trial across multiple sites in urban, regional, and remote locations. Participants will be Aboriginal and Torres Strait Islander people aged 16 years and over who have used methamphetamine at least weekly for the previous 3 months. They will be recruited online and via health services. During the intervention phase, participants will have access to the online intervention for 6 weeks with optional telephone or face-to-face support provided by participating health services. The primary outcome measure will be the number of days the participant used methamphetamine over the past 4 weeks compared to wait-list controls, assessed at baseline, 1, 2, and 3 months. Secondary outcomes will include help-seeking, readiness to change, severity of dependence, and psychological distress. Any important changes to the protocol will be agreed upon by the trial management committee and communicated to all relevant parties, including trial site representatives and the trial registry. Recruitment will commence in July 2019, and results are expected in early 2021. This research is funded by National Health and Medical Research Council project grant #1100696. The primary sponsor for the trial is the South Australian Health and Medical Research Institute. A trial management committee with representation from the participating health services, chief investigators, other Aboriginal experts, and consumers will oversee procedures, trial conduct, analysis, and reporting of the results. The trial of this online intervention builds on existing research supporting the effectiveness of Web-based therapies for a range of psychological and other health-related issues including substance use. If successful, the We Can Do this online intervention will increase the range of options available to Aboriginal people seeking to reduce or stop methamphetamine use. It may provide a pathway into treatment for people who may otherwise be disengaged with health services for a range of reasons and will be a culturally appropriate, evidence-based resource for health practitioners to offer their clients. Australian New Zealand Clinical Trials Registry ACTRN12619000134123p; https://www.anzctr.org.au/ Trial/Registration/TrialReview.aspx?id=376088&isReview=true. PRR1-10.2196/14084.

Sections du résumé

BACKGROUND BACKGROUND
Methamphetamine use is of deep concern to Aboriginal and Torres Strait Islander communities, but access to culturally appropriate treatment resources and services is limited. Web-based programs have potential as flexible and cost-effective additions to the range of treatment options available to Aboriginal people. The We Can Do This online intervention is designed to incorporate evidence-based therapies in a culturally relevant format using narratives from Aboriginal people to contextualize the therapeutic content.
OBJECTIVE OBJECTIVE
The goal of the research will be to test the effectiveness of the online intervention in a wait-list controlled randomized trial across multiple sites in urban, regional, and remote locations.
METHODS METHODS
Participants will be Aboriginal and Torres Strait Islander people aged 16 years and over who have used methamphetamine at least weekly for the previous 3 months. They will be recruited online and via health services. During the intervention phase, participants will have access to the online intervention for 6 weeks with optional telephone or face-to-face support provided by participating health services. The primary outcome measure will be the number of days the participant used methamphetamine over the past 4 weeks compared to wait-list controls, assessed at baseline, 1, 2, and 3 months. Secondary outcomes will include help-seeking, readiness to change, severity of dependence, and psychological distress. Any important changes to the protocol will be agreed upon by the trial management committee and communicated to all relevant parties, including trial site representatives and the trial registry.
RESULTS RESULTS
Recruitment will commence in July 2019, and results are expected in early 2021. This research is funded by National Health and Medical Research Council project grant #1100696. The primary sponsor for the trial is the South Australian Health and Medical Research Institute. A trial management committee with representation from the participating health services, chief investigators, other Aboriginal experts, and consumers will oversee procedures, trial conduct, analysis, and reporting of the results.
CONCLUSIONS CONCLUSIONS
The trial of this online intervention builds on existing research supporting the effectiveness of Web-based therapies for a range of psychological and other health-related issues including substance use. If successful, the We Can Do this online intervention will increase the range of options available to Aboriginal people seeking to reduce or stop methamphetamine use. It may provide a pathway into treatment for people who may otherwise be disengaged with health services for a range of reasons and will be a culturally appropriate, evidence-based resource for health practitioners to offer their clients.
TRIAL REGISTRATION BACKGROUND
Australian New Zealand Clinical Trials Registry ACTRN12619000134123p; https://www.anzctr.org.au/ Trial/Registration/TrialReview.aspx?id=376088&isReview=true.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) UNASSIGNED
PRR1-10.2196/14084.

Identifiants

pubmed: 33932278
pii: v8i7e14084
doi: 10.2196/14084
pmc: PMC6786845
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e14084

Informations de copyright

©Rachel Reilly, Rebecca McKetin, Handan Wand, Julia Butt, Matthew Smout, Nadine Ezard, Katherine Conigrave, Yvonne Clark, Brendan Quinn, Carla Treloar, Dennis Gray, Adrian Dunlop, Yvette Roe, James Ward. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 26.07.2019.

Références

Addiction. 2015 Jan;110(1):120-8
pubmed: 25220170
J Med Internet Res. 2015 Apr 29;17(4):e105
pubmed: 25925801
Addiction. 1995 May;90(5):607-14
pubmed: 7795497
BMC Psychiatry. 2012 Jun 25;12:67
pubmed: 22731926
Australas Psychiatry. 2018 Aug;26(4):417-421
pubmed: 29533079
Drug Alcohol Rev. 2017 Mar;36(2):160-170
pubmed: 27286742
J Med Internet Res. 2008 Jun 30;10(2):e16
pubmed: 18653440
Drug Alcohol Rev. 2014 Jan;33(1):33-42
pubmed: 24206571
Drug Alcohol Rev. 2008 May;27(3):309-17
pubmed: 18368613
J Behav Med. 2012 Jun;35(3):347-63
pubmed: 21695405
Br J Addict. 1992 May;87(5):743-54
pubmed: 1591525
BMJ Open. 2017 Jan 27;7(1):e013518
pubmed: 28132007
Addiction. 2014 May;109(5):798-806
pubmed: 24400972
Behav Cogn Psychother. 2009 Mar;37(2):129-40
pubmed: 19364414
JAMA Psychiatry. 2013 Mar;70(3):319-24
pubmed: 23303471
J Med Internet Res. 2014 Dec 10;16(12):e280
pubmed: 25498835
Psychol Med. 1997 Jul;27(4):861-73
pubmed: 9234464
Addict Behav. 2015 Dec;51:165-70
pubmed: 26275843
Subst Abus. 2010 Apr;31(2):98-107
pubmed: 20408061
Psychol Med. 2002 Aug;32(6):959-76
pubmed: 12214795

Auteurs

Rachel Reilly (R)

Infectious Diseases Aboriginal Health, Aboriginal Health Equity, South Australian Health and Medical Research Institute, Adelaide, Australia.
College of Medicine and Public Health, Flinders University, Bedford Park, Australia.

Rebecca McKetin (R)

National Drug Research Institute, Curtin University, Perth, Australia.

Handan Wand (H)

Kirby Institute, University of New South Wales, Sydney, Australia.

Julia Butt (J)

National Drug Research Institute, Curtin University, Perth, Australia.

Matthew Smout (M)

School of Psychology, Social Work and Social Policy, University of South Australia, Adelaide, Australia.

Nadine Ezard (N)

National Centre for Clinical Research on Emerging Drugs, St Vincent's Hospital, Sydney, Australia.
University of New South Wales, Sydney, Australia.

Katherine Conigrave (K)

Drug Health Services, Royal Prince Alfred Hospital, Camperdown, Australia.
Discipline of Addiction Medicine, University of Sydney, Camperdown, Australia.

Yvonne Clark (Y)

Aboriginal Families Health Research Partnership, South Australian Health and Medical Research Institute, Adelaide, Australia.

Brendan Quinn (B)

Australian Institute of Family Studies, Melbourne, Australia.

Carla Treloar (C)

Centre for Social Research in Health, Social Policy Research Centre, University of New South Wales, Sydney, Australia.

Dennis Gray (D)

National Drug Research Institute, Curtin University, Perth, Australia.

Adrian Dunlop (A)

School of Medicine and Public Health, University of Newcastle, Newcastle, Australia.
Drug and Alcohol Clinical Services, Hunter New England Health, Newcastle, Australia.

Yvette Roe (Y)

Molly Wardaguga Research Centre, Charles Darwin University, Darwin, Australia.

James Ward (J)

Infectious Diseases Aboriginal Health, Aboriginal Health Equity, South Australian Health and Medical Research Institute, Adelaide, Australia.
College of Medicine and Public Health, Flinders University, Bedford Park, Australia.

Classifications MeSH